Effective and clinically meaningful non-hormonal hot flash therapies

Maturitas

Volumn 72, Issue 1, 2012, Pages 6-12

  Guttuso Jr , Thomas ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Clinical trial; Flush; Hot flash; Menopause; Methodology; Treatment

Indexed keywords

BELLADONNA ALKALOID PLUS ERGOTAMINE TARTRATE PLUS PHENOBARBITAL; CITALOPRAM; CLONIDINE; CONJUGATED ESTROGEN; DAIDZEIN; DESVENLAFAXINE; ESCITALOPRAM; FLUOXETINE; GABAPENTIN; GENISTEIN; ISOFLAVONE; ISOFLAVONE DERIVATIVE; METHYLDOPA; OXYBUTYNIN; PLACEBO; PRIMROSE OIL; TIBOLONE; VENLAFAXINE;

CHINESE HERB; CIMICIFUGA RACEMOSA; DRUG EFFICACY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; MEDLINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RED CLOVER; REVIEW; SOYBEAN; SYSTEMATIC REVIEW;

ACTAEA; AMINES; ANTICONVULSANTS; CYCLOHEXANECARBOXYLIC ACIDS; CYCLOHEXANOLS; ESTROGEN REPLACEMENT THERAPY; FEMALE; GAMMA-AMINOBUTYRIC ACID; HOT FLASHES; HUMANS; ISOFLAVONES; MANDELIC ACIDS; MENOPAUSE; PHYTOTHERAPY; PLANT EXTRACTS; SOYBEANS;

CIMICIFUGA DAHURICA;

EID: 84859541352     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2012.01.023     Document Type: Review

References (92)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33. (Pubitemid 34761611)
2. Collaborators MWS. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
3. Lobo RA, McCormick W, Singer F, Roy S. Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Obstet Gynecol 1984;63:1-5. (Pubitemid 14221909)
4. Karakoc B, Erenus M. Compliance considerations with hormone replacement therapy. Menopause 1998;5:102-6. (Pubitemid 28283039)
5. U.S. Department of Health and Human Services FDA. Guidance for Industry: Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms-recommendations for clinical evaluation, 1/2003. Available at: www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ ucm071643.pdf [accessed 01.09.10].
6. European Medicines Agency EMEA. Guideline of clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. Available at: http://www. emea.europa.eu/pdfs/ human/ewp/002197en.pdf [accessed 05.10.10].
7. Loprinzi CL, Diekmann B, Novotny PJ, Stearns V, Sloan JA. Newer anti-depressants and gabapentin for hot flashes: a discussion of trial duration. Menopause 2009;16:883-7.
8. Bergmans MG, Merkus JM, Corbey RS, Schellekens LA, Ubachs JM. Effect of bellergal retard on climacteric complaints: a double-blind, placebo-controlled study. Maturitas 1987;9:227-34. (Pubitemid 17163570)
9. Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005;105:161-6. (Pubitemid 40189927)
10. Upmalis DH, Lobo R, Bradley L, Warren M, Cone FL, Lamia CA. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2000;7:236-42. (Pubitemid 30445953)
11. Guttuso T, Evans M. Minimum trial duration to reasonably assess long-term efficacy of nonhormonal hot flash therapies. J Womens Health (Larchmt) 2010;19:699-702.
12. European Medicines Agency EMEA. Withdrawal assessment report for Pristiqs. Available at: http://wwwemeaeuropaeu/humandocs/PDFs/EPAR/pristiqs/H- 794-WARpdf [accessed 02.09.08].
13. Wyrwich KW, Spratt DI, Gass M, Yu H, Bobula JD. Identifying meaningful differences in vasomotor symptoms among menopausal women. Menopause 2008;15:698-705.
14. Broderick JE, Schwartz JE, Vikingstad G, Pribbernow M, Grossman S, Stone AA. The accuracy of pain and fatigue items across different reporting periods. Pain 2008;139:146-57.
15. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005;366:818-24. (Pubitemid 41557381)
16. Simon JA, LaGuardia KD. Extended-release oxybutynin relieves vasomotor symptoms in healthy postmenopausal women. Obstet Gynecol 2007;109:76S.
17. Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a doubleblind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 2009;200, 238.e1-.e10.
18. Bouchard P, Panay N, de Villiers TJ, et al. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric 2011.
19. Reddy SY, Warner H, Guttuso Jr T, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006;108:41-8. (Pubitemid 44336843)
20. Evans M, Elliott JG, Sharma P, Berman R, Guthrie N. The effect of synthetic genistein on menopause symptom management in healthy postmenopausal women: a multi-center, randomized, placebo-controlled study. Maturitas 2011;68:189-96.
21. Faure ED, Chantre P, Mares P. Effects of a standardized soy extract on hot flushes: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2002;9:329-34. (Pubitemid 36701892)
22. Nahas EA, Nahas-Neto J, Orsatti FL, Carvalho EP, Oliveira ML, Dias R. Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study. Maturitas 2007;58:249-58. (Pubitemid 350103531)
23. Rotem C, Kaplan B. Phyto-female complex for the relief of hot flushes, night sweats and quality of sleep: randomized, controlled, double-blind pilot study. Gynecol Endocrinol 2007;23:117-22. (Pubitemid 46481021)
24. FDA. FDA Public Health Advisory: suicidal thoughts and behavior antiepileptic drugs. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm100195.htm [accessed 18.01.12].
25. Guzman G, Kallwitz ER, Wojewoda C, et al. Liver injury with features mimicking autoimmune hepatitis following the use of black cohosh. Case Report Med 2009, 2009:918156.
26. Teschke R. Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. A critical review. Menopause 2010;17:426-40.
27. Williamson-Hughes PS, Flickinger BD, Messina MJ, Empie MW. Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: a critical review of published studies. Menopause 2006;13:831-9. (Pubitemid 44435039)
28. Thacker HL. Assessing risks and benefits of nonhormonal treatments for vasomotor symptoms in perimenopausal and postmenopausal women. J Womens Health (Larchmt) 2011;20:1007-16.
29. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057-71. (Pubitemid 44794007)
30. Hall E, Frey BN, Soares CN. Non-hormonal treatment strategies for vasomotor symptoms: a critical review. Drugs 2011;71:287-304.
31. Fugate SE, Church CO. Nonestrogen treatment modalities for vasomotor symptoms associated with menopause. Ann Pharmacother 2004;38:1482-99. (Pubitemid 39100205)
32. Rada G, Capurro D, Pantoja T, et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 2010:CD004923.
33. Cheema D, Coomarasamy A, El-Toukhy T. Non-hormonal therapy of postmenopausal vasomotor symptoms: a structured evidence-based review. Arch Gynecol Obstet 2007;276:463-9. (Pubitemid 47415761)
34. Krebs EE, Ensrud KE, MacDonald R, Wilt TJ. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 2004;104:824-36. (Pubitemid 40458814)
35. Lethaby AE, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007:CD001395.
36. This P, de Cremoux P, Leclercq G, Jacquot Y. A critical view of the effects of phytoestrogens on hot flashes and breast cancer risk. Maturitas 2011;70:222-6.
37. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002;137:805-13. (Pubitemid 35334452)
38. Bolanos R, Del Castillo A, Francia J. Soy isoflavones versus placebo in the treatment of climacteric vasomotor symptoms: systematic review and metaanalysis. Menopause 2010;17:660-6.
39. Low Dog T. Menopause: a review of botanical dietary supplements. Am J Med 2005;118:98-108.
40. Shams T, Setia MS, Hemmings R, McCusker J, Sewitch M, Ciampi A. Efficacy of black cohosh-containing preparations on menopausal symptoms: a metaanalysis. Altern Ther Health Med 2010;16:36-44.
41. Cheng G, Wilczek B, Warner M, Gustafsson JA, Landgren BM. Isoflavone treatment for acute menopausal symptoms. Menopause 2007;14: 468-73.
42. D'Anna R, Cannata ML, Atteritano M, et al. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebo-controlled study. Menopause 2007;14:648-55. (Pubitemid 47051957)
43. D'Anna R, Cannata ML, Marini H, et al. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study. Menopause 2009;16:301-6.
44. Jeri AR. The use of an isoflavone supplement to relieve hot flashes. Female Patient 2002;27:35-7.
45. Kaszkin-Bettag M, Ventskovskiy BM, Solskyy S, et al. Confirmation of the efficacy of ERr 731 in perimenopausal women with menopausal symptoms. Altern Ther Health Med 2009;15:24-34.
46. Lipovac M, Chedraui P, Gruenhut C, et al. The effect of red clover isoflavone supplementation over vasomotor and menopausal symptoms in postmenopausal women. Gynecol Endocrinol 2011.
47. van de Weijer PH, Barentsen R. Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas 2002;42:187-93. (Pubitemid 34876810)
48. Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009;200, 172.e1-e10.
49. Geller SE, Shulman LP, van Breemen RB, et al. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause 2009;16:1156-66.
50. Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006;145:869-79. (Pubitemid 351639962)
51. Speroff L, Gass M, Constantine G, Olivier S. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:77-87.
52. Pfizer. Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women. Available at: http://clinicaltrials.gov/ct2/show/NCT00683800 [accessed 02.01.12].
53. FDA. Pfizer Receives Complete Response Letter From FDA For Moderate- To-Severe Vasomotor Symptoms (VMS) Indication For PRISTIQ® (desvenlafaxine) Extended Release Tablets, 09/2011. Available at: www.pfizer.com/files/news/ pristiq statement 090811.pdf [accessed 23.12.11].
54. Library TF. FDA requests study before approving drug for hot flashes. Available at: http://www.thefreelibrary.com/FDA+requests+study+before+ approving+drug+for+hot+flashes.-a0169596562 [accessed 03.01.12].
55. Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010;303:1401-9.
56. Gibbons RD, Hur K, Brown CH, Mann JJ. Gabapentin and suicide attempts. Pharmacoepidemiol Drug Safe 2010;19:1241-7.
57. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20: 327-36. (Pubitemid 44175300)
58. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000;132:788-93. (Pubitemid 30317793)
59. Andersen O, Engebretsen T, Solberg VM, Orbo A. alpha-Methyldopa for climacteric hot flushes. A double-blind, randomized, cross-over study. Acta Obstet Gynecol Scand 1986;65:405-9. (Pubitemid 16015174)
60. Boekhout AH, Vincent AD, Dalesio OB, et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2011;29:3862-8.
61. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. Jama 2011;305:267-74.
62. Suvanto-Luukkonen E, Koivunen R, Sundstrom H, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005;12:18-26. (Pubitemid 40204889)
63. Guttuso Jr T, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003;101:337-45. (Pubitemid 36170136)
64. Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol 2002;20:1449-55. (Pubitemid 34260522)
65. Dalais FS, Rice GE, Wahlqvist ML, et al. Effects of dietary phytoestrogens in postmenopausal women. Climacteric 1998;1:124-9. (Pubitemid 128691301)
66. Murkies AL, Lombard C, Strauss BJ, Wilcox G, Burger HG, Morton MS. Dietary flour supplementation decreases post-menopausal hot flushes: effect of soy and wheat. Maturitas 1995;21:189-95.
67. Lewis JE, Nickell LA, Thompson LU, Szalai JP, Kiss A, Hilditch JR. A randomized controlled trial of the effect of dietary soy and flaxseed muffins on quality of life and hot flashes during menopause. Menopause 2006;13:631-42. (Pubitemid 44079533)
68. Penotti M, Fabio E, Modena AB, Rinaldi M, Omodei U, Vigano P. Effect of soy-derived isoflavones on hot flushes, endometrial thickness, and the pulsatility index of the uterine and cerebral arteries. Fertil Steril 2003;79:1112-7. (Pubitemid 36547847)
69. Khaodhiar L, Ricciotti HA, Li L, et al. Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women. Menopause 2008;15:125-32.
70. Aso T, Uchiyama S, Matsumura Y, et al. A Natural S-(-)Equol Supplement Alleviates Hot Flushes and Other Menopausal Symptoms in Equol Non-producing Postmenopausal Japanese Women. J Womens Health (Larchmt) 2012;21:92-100.
71. Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De Aloysio D. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 1998;91:6-11. (Pubitemid 28042324)
72. Crisafulli A, Marini H, Bitto A, et al. Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebocontrolled study. Menopause 2004;11:400-4. (Pubitemid 40372093)
73. Ferrari A. Soy extract phytoestrogens with high dose of isoflavones for menopausal symptoms. J Obstet Gynaecol Res 2009;35:1083-90.
74. Baber RJ, Templeman C, Morton T, Kelly GE, West L. Randomized placebocontrolled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric 1999;2:85-92. (Pubitemid 29333647)
75. Knight DC, Howes JB, Eden JA. The effect of Promensil, an isoflavone extract, on menopausal symptoms. Climacteric 1999;2:79-84. (Pubitemid 29333646)
76. Tice JA, Ettinger B, Ensrud K, Wallace R, Blackwell T, Cummings SR. Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. Jama 2003;290:207-14. (Pubitemid 37430059)
77. Atkinson C, Warren RM, Sala E, et al. Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165]. Breast Cancer Res 2004;6:R170-9.
78. Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001;19:2739-45. (Pubitemid 32441380)
79. Frei-Kleiner S, Schaffner W, Rahlfs VW, Bodmer C, Birkhauser M. Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. Maturitas 2005;51:397-404. (Pubitemid 41019367)
80. Verhoeven MO, van der Mooren MJ, van de Weijer PH, Verdegem PJ, van der Burgt LM, Kenemans P. Effect of a combination of isoflavones and Actaea racemosa Linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week randomized, placebo-controlled, double-blind study. Menopause 2005;12:412-20. (Pubitemid 41098654)
81. van der Sluijs CP, Bensoussan A, Chang S, Baber R. A randomized placebocontrolled trial on the effectiveness of an herbal formula to alleviate menopausal vasomotor symptoms. Menopause 2009;16:336-44.
82. Lucas M, Asselin G, Merette C, Poulin MJ, Dodin S. Effects of ethyleicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Menopause 2008;16:357-66.
83. Xia Y, Zhao Y, Ren M, et al. A randomized double-blind placebo-controlled trial of a Chinese herbal medicine preparation (Jiawei Qing'e Fang) for hot flashes and quality of life in perimenopausal women. Menopause 2012;19:1-11.
84. Plotnikoff GA, Watanabe K, Torkelson C, La Valleur J, Radosevich DM. The TU-025 keishibukuryogan clinical trial for hot flash management in postmenopausal women: results and lessons for future research. Menopause 2011;18:886-92.
85. Abdali K, Khajehei M, Tabatabaee HR. Effect of St John's wort on severity, frequency, and duration of hot flashes in premenopausal, perimenopausal and postmenopausal women: a randomized, double-blind, placebo-controlled study. Menopause 2010;17:326-31.
86. Al-Akoum M, Maunsell E, Verreault R, Provencher L, Otis H, Dodin S. Effects of Hypericum perforatum (St. John's wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial. Menopause 2009;16: 307-14.
87. van Die MD, Burger HG, Bone KM, Cohen MM, Teede HJ. Hypericum perforatum with Vitex agnus-castus in menopausal symptoms: a randomized, controlled trial. Menopause 2009;16:156-63.
88. Simbalista RL, Sauerbronn AV, Aldrighi JM, Areas JA. Consumption of a flaxseedrich food is not more effective than a placebo in alleviating the climacteric symptoms of postmenopausal women. J Nutr 2010;140:293-7.
89. Garcia JT, Gonzaga F, Tan D, Ng TY, Oei PL, Chan CW. Use of a multibotanical (Nutrafem) for the relief of menopausal vasomotor symptoms: a double-blind, placebo-controlled study. Menopause 2010;17:303-8.
90. Auerbach L, Rakus J, Bauer C, et al. Pomegranate seed oil in women with menopausal symptoms: a prospective randomized, placebo-controlled, double-blinded trial. Menopause 2012.
91. Grady D, Sawaya GF, Johnson KC, et al. MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause 2009;16:458-65.
92. Haines CJ, Lam PM, Chung TK, Cheng KF, Leung PC. A randomized, double-blind, placebo-controlled study of the effect of a Chinese herbal medicine preparation (Dang Gui Buxue Tang) on menopausal symptoms in Hong Kong Chinese women. Climacteric 2008;11:244-51.